GSK, 23andMe sign four-year drug-discovery partnership
Collaboration will leverage genetic testing company's data resources and pharma companies drug-development expertise.
Collaboration will leverage genetic testing company's data resources and pharma companies drug-development expertise.
There are over 70,000 genetic tests on the market and up to 10 new ones make an appearance every day. Many offer exciting prospects for healthcare, but numerous companies make claims such as being able to customize a diet to fit one's genomic profile or predicting the athletic abilities of one's children.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Distrust in genetic sequencing and medical testing abound, but the fact is that genomic medicine is a breakthrough tool for diagnosis and treatment.
The market for reproductive genetic testing historically been dominated by carrier screening but progress is being made in different methods, including non-invasive prenatal testing.
The goal of the La Jolla, California-based company, is to make genomic testing readily accessible and affordable for everyone through employer plans.
Color Genomics' latest test highlights the quandary of genetic testing colliding with value-based care: Is the push to test taking preventive medicine in the wrong direction?
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Dr. Michael Dulin, Chief Medical Officer with data analytics business Tresata who also works as a family physician, shared his experience of genetic testing at the HIMSS Precision Medicine Summit in Boston this week.
Not all direct-to-consumer tests tell the truth, the whole truth, and nothing but the truth. So where do modern consumers stand?
What good is genetic testing if the patient doesn't understand what it means or how to apply that knowledge? Not a lot, which is why Genome Medical was founded to connect people throughout America with genetic counselors and geneticists.
Sean George believes that the genetic testing market will see consolidation and those that survive will provide low-cost high value tests to a wide swathe of the population.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The two companies are perched on a risky, competitive genetic testing market valued in 2015 at $3 billion.
There are many thousands of genetic tests out there but many of them are useful for research purposes and aren't clinically relevant.
“There’s not enough money in the average person’s pocket to take care of the increases in premiums companies would have to charge,” said Dr. Richard Snyder, senior vice president and chief medical officer for Independence Blue Cross.
The sheer number of genetic tests has exploded in the past decade or so. There are now thousands of different testable genetic disorders. In fact, demand for genetic tests has been strong since 2013.
“Our ability to sequence genes has gotten ahead of our ability to know what it means,” said Eric P. Winer, the director of the breast oncology program at Harvard’s Dana-Farber Cancer Institute.